EOLS

6.6604.86%
DN

David N. Gill

Independent Director

Mr. David N. Gill is Director of Bridge to Life Ltd. Mr. Gill is Independent Non-Executive Chair of the Board of Telix Pharmaceuticals Limited from August 31, 2026 and as its Independent Non-Executive Director since May 11, 2026. He serves as Director at Perimetrics Inc. since 2022. He serves as Chairman of the Board at Novum Medical, Inc. He has been Chief Financial Officer at Perspectum Group plc since February 2021. Mr. Gill serves as Director at Strongbridge Biopharma plc since September 3, 2019. He has been Director at Bio2 Technologies, Inc. since December 2019. He served as the Chairman of Melinta Therapeutics Inc. since August 05, 2019 until April 20, 2020. Since 2012, he served as Director at Melinta Therapeutics, Inc. (formerly known as Cempra, Inc.) until April 20, 2020. Mr. Gill served as Chief Financial Officer of Perspectum Ltd., until October 2021. Mr. Gill has been a Director at Evolus, Inc since February 2018. He served as the Chief Financial Officer of TransEnterix, Inc. from March 2009 to February 2011. He has worked in the medical device and life sciences industries. He serves as Director of RapidPulse, Inc. He is Director of Allucent LLC, huMannity Medtec (formerly Alfred Mann Foundation), Alpha Source Inc and Healthtronics, Inc. He served in a variety of senior executive leadership roles for several medical device and information technology companies. He served as the Chief Financial Officer, Senior Vice President and Treasurer of Nxstage Medical, Inc. from July 2005 to November 2006 and also served its Principal Accounting Officer. He served as Chief Financial Officer and Corporate Vice President of Siemens Molecular Imaging, Inc. (formerly, CTI Molecular Imaging, Inc.) since September 2004 and served as its Principal Accounting Officer. He served as Senior Vice President of Siemens Molecular Imaging, Inc. from January 2002 to May 2005. He served as the President and Chief Operating Officer of Siemens Molecular Imaging, Inc. from January 2001 to August 2001 and previously from February 2000 to March 2001. He served as the President and Chief Operating Officer of Interland Inc and its Chief Financial Officer from July 1996. He served as Executive Vice President of Interland, Inc., since March 2000 and served as its Principal Accounting Officer. He served as Chief Financial Officer of Novoste Corporation from July 1996 to March 2000 and served as its Chief Operating Officer from February 1997 to March 2000. From August 1995 to June 1996, he served as Chief Financial Officer of SPEA Software AG. From 1992 to 1995, Mr. Gill served as President of Dornier Medical Systems, Inc., a Member of the Daimler Benz Group and from 1990 to 1992 he served as Vice President of its Finance. From May to November 2015, Mr. Gill served as the President and Chief Financial Officer of EndoChoice Holdings, Inc. from April 2016 until November 2016. Mr. Gill joined EndoChoice Holdings, Inc. as Chief Financial Officer in from August 2014 to April 2016 and was subsequently appointed President in 2015. He is a Director at Stonebridge Biopharma plc. Mr. Gill served as a Director of Strata Skin Science, Inc. since May 29, 2018 until May 22, 2020. He was an Independent Director of Y mAbs Therapeutics, Inc. since December 2017 until September 16, 2025. He was a Director of Histogenics Corporation (now Ocugen, Inc.) from February 2015 to July 18, 2019. Mr. Gill served as Director at Cempra, Inc. (formerly Cempra Pharmaceuticals) since April 01, 2012. He has been a Director of IsoTis, Inc., since November 2006. He served as Director of INC Research, LLC (now known as Syneos Health) from 2007 to 2010. He also served as a Director of Calypso Medical Technologies, Inc. He served as the Chief Financial Officer of INC Research, LLC (now known as Syneos Health) from February 2011 to August 2013. He served as a Director of LeMaitre Vascular, Inc. from 2006 to July 24, 2008. He served as a Director of Interland Inc., from March 2000 to March 2001. He served as Director of IdleAire, Inc. He served as a Director of Isotis Biologics/IsoTis OrthoBiologics, Inc. from 2006 to 2009. He served as Director of Dornier Medical Systems, Inc. from 1992 to 1995. He serves on the Board of visitors of the Wake Forest University Divinity School. He is a frequent presenter at investment conferences and is well known within the healthcare industry. He was a Certified Public Accountant. Mr. Gill received a Master of Business Administration with honors from Emory University and a Bachelor of Science degree in Accounting from Wake Forest University.

Positions